Wuxi Biologics
Wuxi Biologics, officially known as WuXi AppTec Co., Ltd., is a leading global contract research, development, and manufacturing organisation (CDMO) headquartered in Wuxi, China. Founded in 2010, the company has rapidly expanded its operations across major regions, including the United States and Europe, establishing itself as a key player in the biopharmaceutical industry. Specialising in biologics, Wuxi Biologics offers a comprehensive range of services, from cell line development to commercial manufacturing. Their unique integrated platform streamlines the drug development process, enabling clients to bring innovative therapies to market more efficiently. With a strong commitment to quality and innovation, Wuxi Biologics has achieved significant milestones, including numerous partnerships with leading pharmaceutical companies, solidifying its position as a trusted partner in the global biopharmaceutical landscape.
DitchCarbon Score
How does Wuxi Biologics's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Wuxi Biologics's score of 50 is higher than 73% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Wuxi Biologics's reported carbon emissions
In 2024, Wuxi Biologics, headquartered in China, reported total greenhouse gas emissions of approximately 198,654,000 kg CO2e, comprising 38,346,000 kg CO2e from Scope 1 and 160,308,000 kg CO2e from Scope 2 emissions. Additionally, Scope 3 emissions were recorded at about 24,700,000 kg CO2e, which includes business travel, employee commuting, waste generated in operations, and fuel and energy-related activities. The company has set ambitious climate commitments, aiming to reduce its Scope 1 and 2 greenhouse gas emission intensity by 50% by 2030, using 2020 as the baseline year. Furthermore, Wuxi Biologics has committed to achieving net-zero emissions across its entire value chain by 2050. This includes a near-term target to reduce absolute Scope 1 and 2 emissions by 58.8% by 2034 from a 2024 base year, and a 63.8% reduction in Scope 3 emissions per kg of product produced within the same timeframe. Wuxi Biologics' long-term targets include a 90% reduction in absolute Scope 1 and 2 emissions by 2050, alongside a similar 90% reduction in Scope 3 emissions, which encompasses purchased goods and services, capital goods, and waste generated in operations. These targets align with the Science Based Targets initiative (SBTi) and are consistent with the reductions required to limit global warming to 1.5°C. Overall, Wuxi Biologics is actively working towards significant emissions reductions and sustainability goals, reflecting its commitment to addressing climate change within the pharmaceutical and biotechnology sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Scope 1 | 11,042,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 74,361,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | 00,000,000 | 00,000,000 | 00,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Wuxi Biologics is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
